Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts | Zendy

Thomas Schachner | Zendy; Y ZOU | Zendy; Alexander Oberhuber | Zendy; Thomas Mairinger | Zendy; Alexandar Tzankov | Zendy; Günther Laufer | Zendy; H OTT | Zendy; Johannes Bonatti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts

Author(s) -

Thomas Schachner,

Y ZOU,

Alexander Oberhuber,

Thomas Mairinger,

Alexandar Tzankov,

Günther Laufer,

H OTT,

Johannes Bonatti

Publication year - 2004

Publication title -

european journal of cardio-thoracic surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.303

H-Index - 133

eISSN - 1873-734X

pISSN - 1010-7940

DOI - 10.1016/j.ejcts.2003.07.013

Subject(s) - intimal hyperplasia , medicine , calponin , adventitia , neointimal hyperplasia , immunohistochemistry , hyperplasia , vein , cuff , urology , pathology , vascular smooth muscle , thrombus , natriuretic peptide , surgery , smooth muscle , stent , heart failure , restenosis

C-type natriuretic peptide (CNP), which is produced by vascular endothelial cells, exhibits anti-proliferative and anti-inflammatory effects. Cytotoxic T-lymphocytes may be involved in vein graft disease. Attenuation of vein graft disease necessitates a remodelling of the arterialized vein towards a more contractile phenotype which is characterized, among other factors, by the calponin amount. We investigated the effects of perivascularly applied CNP in a mouse model of vein graft disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research